Mifamurtide for the treatment of osteosarcoma

TA235 Osteosarcoma - mifamurtide: review decision - January 2014 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 104 KB)

TA235 Osteosarcoma - mifamurtide: review proposal - November 2013 information

Appendix A: matrix of stakeholders (PDF 96 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 305 KB)

Osteosarcoma - mifamurtide: equality impact assessment (PDF 70 KB)

Osteosarcoma - mifamurtide: final appraisal determination 2 information

Osteosarcoma - mifamurtide: final appraisal determination document (PDF 275 KB)

Osteosarcoma - mifamurtide: letter from The Department of Health (PDF 42 KB)

Osteosarcoma - mifamurtide: manufacturer submission from Takeda UK (PDF 272 KB)

Osteosarcoma - mifamurtide: Evidence Review Group critique prepared by School of Health and Related Research (ScHARR), The University of Sheffield (PDF 255 KB)

Osteosarcoma - mifamurtide: Evidence Review Group critique - factual accuracy check (PDF 137 KB)

Osteosarcoma - mifamurtide: expert statements August 2011

Osteosarcoma - mifamurtide: Flynn (PDF 26 KB)

Osteosarcoma - mifamurtide: Francis (PDF 30 KB)

Osteosarcoma - mifamurtide: Whelan (PDF 251 KB)

Osteosarcoma - mifamurtide: discounting of health benefits in special circumstances (PDF 68 KB)

Osteosarcoma - mifamurtide: final appraisal determination

Osteosarcoma - mifamurtide: final appraisal determination information

Osteosarcoma - mifamurtide: final appraisal determination (PDF 267 KB)

Osteosarcoma - mifamurtide: response to consultee, commentator and public comments on the 3rd ACD and comments from website consultation (PDF 596 KB)

Osteosarcoma - mifamurtide: consultee and commentator comments on the ACD

Takeda UK (PDF 768 KB)

The Bone Cancer Research Trust (PDF 62 KB)

Sarcoma UK and Rarer Cancers Foundation (PDF 82 KB)

Department of Health (PDF 4 KB)

Royal College of Paediatrics and Child Health (PDF 28 KB)

Welsh Assembly Government (PDF 3.6 KB)

Osteosarcoma - mifamurtide: appraisal consultation

Osteosarcoma - mifamurtide: appraisal consultation document information

Osteosarcoma - mifamurtide: evaluation report

Osteosarcoma - mifamurtide: pre-meeting briefing (PDF 227 KB)

Osteosarcoma - mifamurtide: Evidence Review Group report

Osteosarcoma - mifamurtide: original ERG report, January 2009 (PDF 1.21 MB)

Osteosarcoma - mifamurtide: ERG addendum to original ERG report (January 2009), February 2010 (PDF 279 KB)

Osteosarcoma - mifamurtide: ERG response to factual check, March 2010 (PDF 361 KB)

Osteosarcoma - mifamurtide: non-manufacturer submissions

Osteosarcoma - mifamurtide: Bone Cancer Research Trust and Sarcoma UK (PDF 79 KB)

Osteosarcoma - mifamurtide: NCRI Sarcoma CSG, RCP, RCR, ACP, JCCO (joint submission) (PDF 67 KB)

Osteosarcoma - mifamurtide: Royal College of Nursing (PDF 71 KB)

Osteosarcoma - mifamurtide: Royal College of Pathologists (PDF 80 KB)

Osteosarcoma - mifamurtide: Welsh Assembly Government (PDF 3.6 KB)

Osteosarcoma - mifamurtide: manufacturer submission

Osteosarcoma - mifamurtide: response to clarification questions, December 2008 (IDM Pharma) - 1 (PDF 43 KB)

Osteosarcoma - mifamurtide: Response to clarification questions, December 2008 (IDM Pharma) - 2 (PDF 1.39 MB)

Osteosarcoma - mifamurtide: response to clarification questions, January 2009 (IDM Pharma) - 1 (PDF 452 KB)

Osteosarcoma - mifamurtide: response to clarification questions, January 2009 (IDM Pharma) - 2 (PDF 32 KB)

Osteosarcoma - mifamurtide: response to clarification questions, January 2010 (Takeda) (PDF 283 KB)

Osteosarcoma - mifamurtide: 1st clarification letter to IDM Pharma, November 2008 (PDF 81 KB)

Osteosarcoma - mifamurtide: 2nd clarification letter to IDM Pharma, December 2008 (PDF 129 KB)

Osteosarcoma - mifamurtide: clarification letter to Takeda, January 2010 (PDF 136 KB)

Osteosarcoma - mifamurtide: original manufacturer's submission from IDM Pharma, November 2008 (PDF 1.33 MB)

Osteosarcoma - mifamurtide: manufacturer's updated economic submission from Takeda, December 2009 (PDF 912 KB)

Osteosarcoma - mifamurtide: manufacturer's addendum to updated economic submission (December 2009 submission), February 2010 (PDF 290 KB)

Osteosarcoma - mifamurtide: letter from Department of Health (PDF 40 KB)

Osteosarcoma - mifamurtide: expert written personal statements

Osteosarcoma - mifamurtide: expert written personal statements - Eden (PDF 24 KB)

Osteosarcoma - mifamurtide: expert written personal statements - Francis (PDF 74 KB)

Osteosarcoma - mifamurtide: expert written personal statements - Freemont (PDF 24 KB)

Osteosarcoma - mifamurtide: expert written personal statements - Hurst (PDF 39 KB)

Osteosarcoma - mifamurtide: expert written personal statements - Michelagnoli (PDF 59 KB)

Osteosarcoma - mifamurtide: expert written personal statements - Millington (PDF 63 KB)

Osteosarcoma - mifamurtide: final scope (PDF 41 KB)

Osteosarcoma - mifamurtide: final matrix (PDF 51 KB)

Osteosarcoma - mifamurtide: response to consultee and commentator comments on the draft scope (PDF 79 KB)

Osteosarcoma - mifamurtide: response to consultee and commentator comments on the provisional matrix (PDF 29 KB)